Lifevantage Corp (LFVN) Stock Analysis and Metrics

Lifevantage

NASDAQ: LFVN

$6.61 ▲ +0.34 (+5.42%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap81.31 Mn

P/E14.15

P/S0.42

Div. Yield0.03

Revenue Growth (1y) (Qtr)-25.20

Add ratio to table…

About

LifeVantage Corporation is a wellness enterprise that concentrates on nutrigenomics to create and distribute scientifically validated health products. The firm develops and sells dietary supplements skin and hair care formulations pet supplements and nootropic energy drink mixes. It operates through a direct selling model that relies on a network of independent consultants to market and distribute its offerings. Core brand families include Protandim LifeVantage PhysIQ TrueScience Petandim and AXIO. LifeVantage makes its products available in the United States Japan Australia Canada Mexico Europe and numerous additional markets worldwide.

LifeVantage derives its revenue chiefly from the sale of its product portfolio to end users and independent consultants. The product portfolio encompasses the Protandim line of Nrf2 activators the LifeVantage line which includes the MindBody GLP 1 System Omega+ ProBio IC Bright Rise AM & Reset PM System D3+ and Daily Wellness the PhysIQ line of Fat Burn and Prebiotic supplements the TrueScience line of skin and hair care and Liquid Collagen the Petandim supplement for dogs and the AXIO line of nootropic energy drink mixes. Sales are executed through the consultant network and via the company’s ecommerce platform. In fiscal year 2025 the company recorded total revenue of about $228.5 million with roughly 78% originating in the United States and 11% from Japan. The remainder came from other international markets. Additionally the firm generates recurring income from subscription purchases and credits awarded through its Rewards Circle loyalty program.

LifeVantage occupies a specialized niche in the direct selling sector by merging nutrigenomic science with a multi level marketing framework. Its primary rivals include other direct selling companies such as Herbalife Nu Skin and Avon as well as broad supplement retailers like GNC Vitamin Shoppe and The Vitamin Shoppe. Competitive strengths arise from its clinically backed product suite its Evolve compensation plan that provides frequent payouts and its digital tools like the LifeVantage app that support consultant productivity. The firm also benefits from a culture emphasizing ethical conduct transparent operations and a global customer acquisition program that expands reach without heavy infrastructure investment.

LifeVantage serves two core constituencies: independent consultants who sell the products and customers who buy them for personal consumption. As of June 30, 2025, the firm reported roughly 51,000 active independent consultants and 81,000 active customers worldwide. These participants tend to be entrepreneurial individuals health conscious consumers and people looking for supplemental income or wellness improvement. While the company does not publish specific customer names its base spans households across North America Europe Asia and the Pacific region. The consultant network is active in markets such as the United States Japan Australia Canada Mexico and numerous European nations.

Investment Thesis

▲ Bull case

LifeVantage has strategically diversified beyond its core GLP-1 offering through the acquisition of LoveBiome and development of complementary products like P84, reducing reliance on any single product line; while MINDBODY sales declined 25.2% year-over-year, LoveBiome contributed meaningfully to offsetting this decline, and the company’s pipeline includes additional gut health and nutrigenomics innovations not yet disclosed, suggesting a broader portfolio evolution that could stabilize revenue as consultant engagement improves through targeted incentives and foundational business-building efforts.
The newly appointed CEO Terrence Moorhead brings over thirty years of direct selling leadership experience with a proven track record in brand revitalization and growth acceleration, signaling a potential inflection point in execution capability; despite interim leadership under Beindorff maintaining operational continuity, Moorhead’s August start date aligns with the planned Shopify e-commerce rollout and annual convention in October, creating a concentrated window for strategic initiatives to converge—new leadership, upgraded technology, product launches, and enhanced consultant incentives—all of which could collectively reignite growth momentum in a way the market has not yet priced in given current low expectations.
The VIP bonus program represents a structural shift in consultant motivation by tying rewards to twelve-month volume growth and requiring opt-in commitment from leadership-oriented consultants, which could cultivate a sustainable, high-performing distributor base rather than relying on short-term promotional spikes; combined with Cunningham’s focus on foundational business-building and simplification, this approach addresses root causes of consultant attrition in the Americas (down from 32,000 to 30,000) by fostering deeper engagement and retention, potentially reversing the trend and improving long-term sales productivity per consultant, a factor not yet reflected in current valuation multiples.
LifeVantage’s debt-free balance sheet with $12.5 million in cash and $59 million remaining under its share repurchase authorization provides significant financial flexibility to weather near-term volatility while continuing to return capital; the company generated $5.5 million in operating cash flow YTD despite lower revenue, and management expects similar quarterly run rates in Q4, indicating resilient cash conversion that supports both the 11% dividend increase and opportunistic buybacks, reinforcing shareholder returns even as growth initiatives mature—a dual advantage of stability and yield that is underappreciated in a market focused solely on top-line decline.
The U.S. patent granted for the Healthy Glow Essentials Stack (Protandim NRF2 Synergizer and TruScience Liquid Collagen) validates LifeVantage’s core innovation in nutrigenomics and strengthens its intellectual property moat, particularly as the company prepares to launch its next hero product at the October annual convention; this patent, combined with ongoing Shopify integration and P84’s role as a gut health anchor, positions the company to leverage scientific differentiation in an increasingly crowded wellness market, where branded, evidence-based products command premium loyalty and pricing power—an advantage not fully captured in current earnings multiples amid GLP-1 segment pressures.

LifeVantage has strategically diversified beyond its core GLP-1 offering through the acquisition of LoveBiome and development of complementary products like P84, reducing reliance on any single product line; while MINDBODY sales declined 25.2% year-over-year, LoveBiome contributed meaningfully to offsetting this decline, and the company’s pipeline includes additional gut health and nutrigenomics innovations not yet disclosed, suggesting a broader portfolio evolution that could stabilize revenue as consultant engagement improves through targeted incentives and foundational business-building efforts.
The newly appointed CEO Terrence Moorhead brings over thirty years of direct selling leadership experience with a proven track record in brand revitalization and growth acceleration, signaling a potential inflection point in execution capability; despite interim leadership under Beindorff maintaining operational continuity, Moorhead’s August start date aligns with the planned Shopify e-commerce rollout and annual convention in October, creating a concentrated window for strategic initiatives to converge—new leadership, upgraded technology, product launches, and enhanced consultant incentives—all of which could collectively reignite growth momentum in a way the market has not yet priced in given current low expectations.
The VIP bonus program represents a structural shift in consultant motivation by tying rewards to twelve-month volume growth and requiring opt-in commitment from leadership-oriented consultants, which could cultivate a sustainable, high-performing distributor base rather than relying on short-term promotional spikes; combined with Cunningham’s focus on foundational business-building and simplification, this approach addresses root causes of consultant attrition in the Americas (down from 32,000 to 30,000) by fostering deeper engagement and retention, potentially reversing the trend and improving long-term sales productivity per consultant, a factor not yet reflected in current valuation multiples.
LifeVantage’s debt-free balance sheet with $12.5 million in cash and $59 million remaining under its share repurchase authorization provides significant financial flexibility to weather near-term volatility while continuing to return capital; the company generated $5.5 million in operating cash flow YTD despite lower revenue, and management expects similar quarterly run rates in Q4, indicating resilient cash conversion that supports both the 11% dividend increase and opportunistic buybacks, reinforcing shareholder returns even as growth initiatives mature—a dual advantage of stability and yield that is underappreciated in a market focused solely on top-line decline.
The U.S. patent granted for the Healthy Glow Essentials Stack (Protandim NRF2 Synergizer and TruScience Liquid Collagen) validates LifeVantage’s core innovation in nutrigenomics and strengthens its intellectual property moat, particularly as the company prepares to launch its next hero product at the October annual convention; this patent, combined with ongoing Shopify integration and P84’s role as a gut health anchor, positions the company to leverage scientific differentiation in an increasingly crowded wellness market, where branded, evidence-based products command premium loyalty and pricing power—an advantage not fully captured in current earnings multiples amid GLP-1 segment pressures.

▼ Bear case

LifeVantage remains heavily dependent on the volatile GLP-1 supplement market, where MINDBODY sales drove the 25.2% revenue decline and continue to face intense competition from both pharmaceutical GLP-1 agonists and emerging nutraceutical alternatives; despite LoveBiome’s contribution, the company has not disclosed whether this acquisition can meaningfully replace GLP-1-related revenue streams, and the lack of detail around future complementary products suggests reliance on unproven innovations, leaving the business vulnerable to ongoing category-specific headwinds that management acknowledged by lowering full-year guidance to the low end of prior ranges.
Consultant attrition in the Americas—where revenue fell 28.9% and active accounts dropped from 32,000 to 30,000—reflects deeper systemic issues in distributor engagement and satisfaction that superficial incentive programs like the VIP bonus may not resolve; Cunningham’s emphasis on “foundational approach” and simplification hints at prior over-complication of the business model, yet no concrete metrics were provided on consultant retention rates, productivity trends, or the actual uptake of the VIP program, raising doubts about whether leadership can reverse the trend without addressing underlying consultant dissatisfaction with compensation, support, or market saturation.
The shift to Shopify and e-commerce upgrades, while framed as a long-term investment, introduces execution risk during a period of declining sales, with $2.5 million in YTD capital expenditures up from $1.2 million prior year and no clear timeline for ROI; Aure indicated implementation will roll into Q1 of next fiscal year, meaning benefits are delayed, and the company is spending aggressively on tech while revenue declines, potentially straining cash flow if operating performance does not improve—a mismatch between investment timing and current business deterioration that could amplify losses if sales do not stabilize quickly.
Although LifeVantage maintains a debt-free balance sheet with $12.5 million in cash, the $5.5 million YTD operating cash flow is down significantly from $10.8 million in the prior year, and the company’s ability to sustain similar quarterly run rates in Q4 depends on continued favorable timing of incentive payments and absence of unexpected expenses; with GAAP operating income down to $1.7 million from $4.1 million and adjusted EBITDA margin falling from 11% to 7.3%, the cushion for error is thin, and any further deterioration in sales or increase in costs—such as higher shipping, warehouse, or inventory obsolescence expenses that already pressured gross margin—could quickly erode financial flexibility despite the current cash position.
The appointment of Terrence Moorhead as incoming CEO, while promising on paper, introduces transition risk during a critical period; Moorhead will not join until August, leaving Beindorff in an interim role through Q3, and the company provided no details on how Moorhead’s background in revitalizing brands translates to LifeVantage’s specific challenges in direct selling, nutrigenomics, or GLP-1 competition, leaving investors to rely on unverified optimism about leadership change rather than concrete plans for product innovation, consultant reactivation, or market share recovery in a segment where timing and execution are paramount.

LifeVantage remains heavily dependent on the volatile GLP-1 supplement market, where MINDBODY sales drove the 25.2% revenue decline and continue to face intense competition from both pharmaceutical GLP-1 agonists and emerging nutraceutical alternatives; despite LoveBiome’s contribution, the company has not disclosed whether this acquisition can meaningfully replace GLP-1-related revenue streams, and the lack of detail around future complementary products suggests reliance on unproven innovations, leaving the business vulnerable to ongoing category-specific headwinds that management acknowledged by lowering full-year guidance to the low end of prior ranges.
Consultant attrition in the Americas—where revenue fell 28.9% and active accounts dropped from 32,000 to 30,000—reflects deeper systemic issues in distributor engagement and satisfaction that superficial incentive programs like the VIP bonus may not resolve; Cunningham’s emphasis on “foundational approach” and simplification hints at prior over-complication of the business model, yet no concrete metrics were provided on consultant retention rates, productivity trends, or the actual uptake of the VIP program, raising doubts about whether leadership can reverse the trend without addressing underlying consultant dissatisfaction with compensation, support, or market saturation.
The shift to Shopify and e-commerce upgrades, while framed as a long-term investment, introduces execution risk during a period of declining sales, with $2.5 million in YTD capital expenditures up from $1.2 million prior year and no clear timeline for ROI; Aure indicated implementation will roll into Q1 of next fiscal year, meaning benefits are delayed, and the company is spending aggressively on tech while revenue declines, potentially straining cash flow if operating performance does not improve—a mismatch between investment timing and current business deterioration that could amplify losses if sales do not stabilize quickly.
Although LifeVantage maintains a debt-free balance sheet with $12.5 million in cash, the $5.5 million YTD operating cash flow is down significantly from $10.8 million in the prior year, and the company’s ability to sustain similar quarterly run rates in Q4 depends on continued favorable timing of incentive payments and absence of unexpected expenses; with GAAP operating income down to $1.7 million from $4.1 million and adjusted EBITDA margin falling from 11% to 7.3%, the cushion for error is thin, and any further deterioration in sales or increase in costs—such as higher shipping, warehouse, or inventory obsolescence expenses that already pressured gross margin—could quickly erode financial flexibility despite the current cash position.
The appointment of Terrence Moorhead as incoming CEO, while promising on paper, introduces transition risk during a critical period; Moorhead will not join until August, leaving Beindorff in an interim role through Q3, and the company provided no details on how Moorhead’s background in revitalizing brands translates to LifeVantage’s specific challenges in direct selling, nutrigenomics, or GLP-1 competition, leaving investors to rely on unverified optimism about leadership change rather than concrete plans for product innovation, consultant reactivation, or market share recovery in a segment where timing and execution are paramount.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Packaged Foods

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	KHC	Kraft Heinz Co	30.29 Bn	-5.26	1.21	21.13 Bn
2	GIS	General Mills Inc	19.35 Bn	-2,199.07	1.05	13.47 Bn
3	HRL	Hormel Foods Corp /De/	13.90 Bn	29.79	1.14	2.86 Bn
4	MKC	Mccormick & Co Inc	13.45 Bn	18.95	1.82	3.61 Bn
5	MICC	Magnum Ice Cream Co N.V.	10.95 Bn	31.87	1.18	3.85 Bn
6	SFD	Smithfield Foods Inc	10.34 Bn	41.19	0.66	2.00 Bn
7	DAR	Darling Ingredients Inc.	9.92 Bn	57.52	1.66	4.13 Bn
8	OTLY	Oatly Group AB	8.23 Bn	-54.03	9.21	0.00 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password